Abstract
A systematic review and meta-analysis by Yang and colleagues, published in JAMA Open Network in October 2021, found that 5-HT1F receptor agonists or “ditans” (lasmiditan) and calcitonin gene-related peptide antagonists or “gepants” (rimegepant and ubrogepant) were not as effective in reducing pain 2 hours post-dose as compared to triptans. However, the study findings concluded gepants were less likely to cause mild to moderate adverse events compared to triptans.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
